Etienna Bio, Inc. Announces Formation of Scientific Advisory Board with Renowned UMass Chan LeadersSilvia Corvera, MD, and Michael Czech, PhD, Join SAB to Advance Autologous Regenerative Cell Platform
Etienna Bio Secures Exclusive Worldwide License from UMass Chan Medical School for Novel Adipose-Derived Regenerative PlatformLEAWOOD, Kan., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Etienna Bio, Inc., a biotechnology company focused on next-generation autologous and cell-enabled biomaterials for regenerative and aesthetic applications, today announced that it has entered into an exclusive, worldwide license agreement with the UMass Chan Medical School to develop and commercialize a proprietary adipose-derived cellular and matrix technology platform.
